MLU Prostate Cancer Study

A phase 3, randomized, double-blind, placebo-controlled study of Mevrometostat (pf-06821497) with Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer

A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC)

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 2/3 Study of Lutetium Rosopatamab Tetraxetan plus Standard of Care vs. Standard of Care alone for Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously Treated with Androgen Receptor Pathway Inhibitors

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best SupportiveCare Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

A phase 3 study of MK-5684 versus alternative NHA in mCRPC